Deals this week: Vectorious Medical Technologies, TAE Life Sciences, GI Dynamics

16 March 2018 (Last Updated March 16th, 2018 15:06)

Vectorious Medical Technologies Ltd has raised $7.3m in a series B financing round led by Broadview Ventures, GEOC, and individual investors.

Vectorious Medical Technologies Ltd has raised $7.3m in a series B financing round led by Broadview Ventures, GEOC, and individual investors.

The company also received a $2.2m grant under the European Union’s Horizon 2020 R&D programme and the Israel Innovation Authority.

Based in Israel, Vectorious is involved in the development of the novel cardiac monitoring system.

The company plans to use the proceeds towards business expansion.

TAE Life Sciences, a subsidiary of TAE Technologies, has raised $40m in a series A funding round led by ARTIS Ventures.

The US-based medical technology company will use the funds towards the development of its Boron Neutron Capture Therapy (BNCT) for the treatment of head and neck, glioblastoma multiforme (GBM) cancer.

GI Dynamics Inc has raised A$1.06m ($0.83m) through a second tranche of a private placement of 30.3 million chess depositary interests (CDIs) priced at A$0.03 ($0.027) per CDI.

The company previously raised A$0.99m ($0.79m) in the first tranche of private placement of 28.4 million CDIs priced at A$0.03 ($0.023) per CDI.

Based in the US, GI Dynamics is a medical device company engaged in the design and application of devices and disease management solutions.

The proceeds are intended to be used for funding the development of EndoBarrier and for working capital purposes.

“The company plans to use the proceeds to develop a distribution network in the US and new devices for children and adults.”

Incereb has raised €0.75m ($0.93m) through a third financing round led by HBAN angel network.

Based in Ireland, Incereb is a medical device company involved in the development of neonatal and fetal physiological monitoring sensors.

The company plans to use the proceeds to develop a distribution network in the US and new devices for children and adults.

Zimmer Biomet Holdings Inc has announced plans to raise $450m and $300m through a public offering of senior unsecured notes due 2021 and 2023.

Based in the US, Zimmer Biomet Holdings is involved in the development of medical devices and medical equipment.

The company plans to use the proceeds to repay $450m of its outstanding 2% notes due in April.

VolitionRX Ltd has raised $8.4m through an underwritten public offering of 3.5 million shares of its common stock priced at $2.4 a share.

Based in Singapore, VolitionRX is a provider of diagnostics tests for cancer and other conditions.

The proceeds are intended to be used for product development and commercialisation, working capital, and general corporate purposes.

Alphatec Holdings Inc plans to raise $50m through the private placement of series B convertible preferred stock and warrants.

Based in the US, Alphatec Holdings is a medical device company involved in the design, development and marketing of spinal fusion technology products.

The company plans to use the funds to acquire SafeOp Surgical and for general corporate purposes.

Qiagen NV has signed a ten-year agreement with Natera Inc to develop cell-free DNA assays for use in its GeneReader next-generation sequencing (NGS) system.

QIAGEN will pay $40m in upfront licensing fees to Natera and $10m in additional milestone payments, as part of the agreement.

Based in the Netherlands, Qiagen is a provider of sample and assay technologies for molecular diagnostics, while Natera is a US-based genetic testing company involved in the development of cell-free DNA testing.